Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking place in New York City on Wednesday, May 7, 2025 beginning at 3:30 p.m. Eastern Time. A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event. About Quince Therapeutics

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025. A replay of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. About Quince Therapeutics Quince Therapeutics, Inc. (NASDAQ:QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology f

Phase 3 NEAT clinical trial exceeds 50% enrollment with new study site activations expected to accelerate screenings and randomization Existing cash position of $40.8 million expected to provide operating runway through Phase 3 topline results into 2026 Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the fiscal year ended December 31, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "Our Phase 3 pivotal NEAT clinical trial has exc

Phase 3 NEAT clinical trial nearing 50% enrollment; company reiterates expectation of enrollment completion in second quarter of 2025 and topline results in fourth quarter of 2025 Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced that it will host an investor webinar today, Friday, February 7, 2025, beginning at 10:00 a.m. Eastern Time, featuring key opinion leader (KOL) Dr. Mary Kay Koenig from UTHealth Houston with a discussion focused on addressing the high unmet need in Ataxia-Telangiectasia (A-T). Quince also disclosed that the company has enrolled 46

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event, on Wednesday, February 12, 2025 beginning at 2:00 p.m. Eastern Time. A live webcast of the fireside chat will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of

Allowance to extend into 2036 patent claims related to method of treating patients with A-T using the company's proprietary EryDex process Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/083,771 entitled Process for the Preparation of Erythrocytes Loaded With One or More Substances of Pharmaceutical Interest and So Obtained Erythrocytes. The newly allowed application covers the method of treating patients with Ataxia-Telangiectasia (A-T) and

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it will host an investor webinar focused on addressing the high unmet need in the company's lead rare pediatric neurodegenerative disease indication, Ataxia-Telangiectasia (A-T). The virtual webinar event will take place on Friday, February 7, 2025, beginning at 10:00 a.m. Eastern Time. The webinar will feature leading A-T key opinion leader (KOL) Mary Kay Koenig, M.D., who will: 1) provide an A-T natural history overview, 2) detail current symptomatic treatment approaches for patients with A-T, 3)

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the online publication of safety data from patients with Ataxia-Telangiectasia (A-T) treated with EryDex for a minimum of 24 months in Frontiers in Neurology. "A-T is a rare pediatric disease with unmet medical need and no approved therapeutic treatment. This post-hoc analysis of patients with A-T treated for a minimum of 24 months in a Phase 3 clinical trial (ATTeST) and an open label extension study, provides data supporting the potential to deliver dexamethasone sodium phosphate encapsulated in a patient's

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, to the company's Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince's SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. Dr. Mauro Magn

Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enrolling patients Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the third quarter ended September 30, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "We are pleased to report accelerating enrollment of our pivotal Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T). As of today, we have enrolled 32

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

Oppenheimer initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $10.00

SCHEDULE 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

DEFA14A - Quince Therapeutics, Inc. (0001662774) (Filer)

DEF 14A - Quince Therapeutics, Inc. (0001662774) (Filer)

PRE 14A - Quince Therapeutics, Inc. (0001662774) (Filer)

S-8 - Quince Therapeutics, Inc. (0001662774) (Filer)

424B5 - Quince Therapeutics, Inc. (0001662774) (Filer)

10-K - Quince Therapeutics, Inc. (0001662774) (Filer)

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

SCHEDULE 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

SCHEDULE 13G - Quince Therapeutics, Inc. (0001662774) (Subject)

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, to the company's Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince's SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. Dr. Mauro Magn

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company's Board of Directors. "We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni's caliber to our Board of Directors," said David Lamond, chairperson of Quince's Board of Directors. "With expertise that spans the continuum from translational to registrational studies and regulatory agency negotiation in several rare diseases, we lo

Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company's corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S.p.A., the international integration of financial and operational activities and ongoing business operations of Quince. Dirk Thye, M.D., Quince's Chief Executive Officer, said, "Charles is a valuable addition to our management team. His considera